Jacobson, Terry A.

Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy

Ridker, P. M., Rifai, N., MacFadyen, J., Glynn, R. J., Jiao, L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Tardif, J.-C., et al. (2022) · Circulation

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 131

Statin safety: an assessment using an administrative claims database

Cziraky, M. J., Willey, V. J., McKenney, J. M., Kamat, S. A., Fisher, M. D., Guyton, J. R., Jacobson, T. A., & Davidson, M. H. (2006) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthPharmacovigilance and Adverse Drug Reactions

Cited by 130

National lipid association annual summary of clinical lipidology 2016

Bays, H. E., Jones, P. H., Orringer, C. E., Brown, W. V., & Jacobson, T. A. (2016) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 128

Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association

Soffer, D. E., Marston, N. A., Maki, K. C., Jacobson, T. A., Bittner, V. A., Peña, J. M., Thanassoulis, G., Martin, S. S., Kirkpatrick, C. F., Virani, S. S., et al. (2024) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 115

Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association

Warden, B. A., Guyton, J. R., Kovacs, A. C., Durham, J. A., Jones, L. K., Dixon, D. L., Jacobson, T. A., & Duell, P. B. (2023) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthMedication Adherence and Compliance

Cited by 111

National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk

Orringer, C. E., Jacobson, T. A., & Maki, K. C. (2019) · Journal of Clinical Lipidology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 103

Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles

Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Jiao, L., Tardif, J.-C., Gregson, J., Pocock, S. J., & Ballantyne, C. M. (2019) · Journal of the American College of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 97

Myopathy with statin–fibrate combination therapy: clinical considerations

Jacobson, T. A. (2009) · Nature Reviews Endocrinology

Lipoproteins and Cardiovascular HealthPharmacogenetics and Drug Metabolism

Cited by 82

Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction

Gaba, P., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2022) · Journal of the American College of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 61

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses

Peterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2021) · Circulation

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 57

Clinical characterization and molecular mechanisms of statin myopathy

Toth, P. P., Harper, C. R., & Jacobson, T. A. (2008) · Expert Review of Cardiovascular Therapy

Lipoproteins and Cardiovascular HealthMuscle Physiology and Disorders

Cited by 55

Effect of health information technology interventions on lipid management in clinical practice: A systematic review of randomized controlled trials

Aspry, K. E., Furman, R., Karalis, D. G., Jacobson, T. A., Zhang, A. M., Liptak, G. S., & Cohen, J. D. (2013) · Journal of Clinical Lipidology

Electronic Health Records SystemsLipoproteins and Cardiovascular Health

Cited by 41

Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia

Rosenson, R. S., Jacobson, T. A., Preiss, D., Djedjos, C. S., Dent, R., Bridges, I., & Miller, M. (2016) · Cardiovascular Drugs and Therapy

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 36

Cardiovascular benefits of icosapent ethyl in patients with and without atrial fibrillation in REDUCE-IT

Olshansky, B., Bhatt, D. L., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., et al. (2023) · Journal of the American Heart Association

Fatty Acid Research and HealthAtrial Fibrillation Management and Outcomes

Cited by 29

REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results

Olshansky, B., Bhatt, D. L., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle Jr, R. T., Juliano, R. A., Jiao, L., et al. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 25

COST-EFFECTIVENESS OF ICOSAPENT ETHYL IN US REDUCE-IT PATIENTS

Weintraub, W. S., Bhatt, D., Zhang, Z., Zhang, C., Sarahfaye, D., Boden, W. E., Steg, P. G., Miller, M., Brinton, E., King, J., et al. (2020) · Journal of the American College of Cardiology

Fatty Acid Research and HealthHealth Systems, Economic Evaluations, Quality of Life

Cited by 13

Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn

Miller, M., Bhatt, D. L., Brinton, E. A., Jacobson, T. A., Steg, P. G., Pineda, A. L., Ketchum, S. B., Doyle, R. T., Tardif, J.-C., & Ballantyne, C. M. (2023) · European Heart Journal Open

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 11

Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT

Szarek, M., Bhatt, D., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Tardif, J. C., Ballantyne, C. M., Ketchum, S. B., Pineda, A. L., et al. (2023) · European Heart Journal

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 9

Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM

Miller, M., Bhatt, D. L., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Pineda, A. L., Tardif, J.-C., & Ballantyne, C. M. (2026) · American Journal of Preventive Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 0